Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 16/20 | 0.37 |
| ▸ | NPY1R | P25929 | 10/20 | 0.37 |
| ▸ | NPY5R | Q15761 | 9/20 | 0.37 |
| ▸ | NPY2R | P49146 | 6/20 | 0.37 |
| ▸ | FURIN | P09958 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23106115 | 0.90 | SMN1; SMN2 (0.33) | FURINSMN1; SMN2 | |
| SCHEMBL21503813 | 0.89 | NPY4R (0.38) | NPY4RNPY1RNPY5RNPY2RFURIN | |
| SCHEMBL21503822 | 0.86 | NPY4R (0.38) | NPY4RNPY1RNPY5RNPY2RFURIN | |
| SCHEMBL19386721 | 0.86 | NPY4R (0.36) | NPY4RNPY1RNPY5RNPY2RSMN1; SMN2 | |
| SCHEMBL23106038 | 0.85 | NPY4R (0.39) | NPY4RNPY1RNPY5RNPY2RFURIN | |
| SCHEMBL15727429 | 0.83 | NPY4R (0.42) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL23106247 | 0.82 | REN (0.33) | — | |
| SCHEMBL23106120 | 0.81 | SIRT6 (0.39) | FURIN | |
| SCHEMBL25503971 | 0.81 | NPY4R (0.41) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL23106118 | 0.81 | NPY4R (0.38) | NPY4RNPY1RNPY5RNPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210079039-A1 | COMPOSITIONS AND METHODS FOR THE SELECTIVE DELIVERY OF THERAPEUTIC AND IMAGING AGENTS | AVELAS ACQUISITION CORPORATION | 2021-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210079039-A1 | COMPOSITIONS AND METHODS FOR THE SELECTIVE DELIVERY OF THERAPEUTIC AND IMAGING AGENTS | PAICS, ANXA3, APOB | NPY4R 2962/4885NPY1R 2878/4885NPY5R 2298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.